| Name | Title | Contact Details |
|---|
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
Sagent Pharmaceuticals is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ChemBridge, Corp. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
FSD Pharma is transforming a large facility in Cobourg, Ontario Canada, into the largest hydroponic indoor cannabis production and processing facility in the world, with multiple business units co-supporting each other, operating under a single roof to exploit economies of scale and operational efficiencies. We are growing the future through innovation!